scholarly article | Q13442814 |
P356 | DOI | 10.1007/S10555-017-9700-2 |
P8608 | Fatcat ID | release_ig5evqdfpvfcnbvvnuv5cn3ypq |
P698 | PubMed publication ID | 29071526 |
P2093 | author name string | Claudia P Miller | |
Joya Chandra | |||
Vidya Gopalakrishnan | |||
Soumen Khatua | |||
Wafik Zaky | |||
Christa Manton | |||
P2860 | cites work | Pediatric medulloblastoma - update on molecular classification driving targeted therapies | Q21129295 |
The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction | Q24292709 | ||
E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC(Cdh1) | Q24296663 | ||
Prophase destruction of Emi1 by the SCF(betaTrCP/Slimb) ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase | Q24304123 | ||
ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor | Q24306428 | ||
Myc protein is stabilized by suppression of a novel E3 ligase complex in cancer cells | Q24321642 | ||
Mdm2 promotes the rapid degradation of p53 | Q24322597 | ||
FBXL2- and PTPL1-mediated degradation of p110-free p85β regulatory subunit controls the PI(3)K signalling cascade | Q24338848 | ||
26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide | Q24535312 | ||
mTOR: from growth signal integration to cancer, diabetes and ageing | Q24633662 | ||
The ubiquitin proteasome system in neuropathology | Q24644208 | ||
Origin and function of ubiquitin-like proteins | Q24651141 | ||
Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
The role of the ubiquitin proteasome system in cerebellar development and medulloblastoma | Q26782159 | ||
Structural basis for the activation of 20S proteasomes by 11S regulators | Q27628418 | ||
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. | Q27851485 | ||
Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition | Q27852966 | ||
The ubiquitin system | Q27860803 | ||
CDC20 and CDH1: a family of substrate-specific activators of APC-dependent proteolysis. | Q27930914 | ||
A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3. | Q27936509 | ||
Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation | Q28137846 | ||
SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 | Q28137860 | ||
Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo | Q28177348 | ||
N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation | Q28207748 | ||
Overexpression of the anaphase promoting complex/cyclosome inhibitor Emi1 leads to tetraploidy and genomic instability of p53-deficient cells | Q28253606 | ||
Introduction to NF-kappaB: players, pathways, perspectives | Q28271022 | ||
The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation | Q28280330 | ||
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation | Q28280958 | ||
Subtypes of medulloblastoma have distinct developmental origins | Q28300616 | ||
Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas | Q36048192 | ||
Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic application | Q36062128 | ||
Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors | Q36108972 | ||
It Takes 15 to Tango: Making Sense of the Many Ubiquitin Ligases of p53. | Q36387588 | ||
A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916) | Q36438027 | ||
Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo | Q36500531 | ||
Post-transcriptional down-regulation of Atoh1/Math1 by bone morphogenic proteins suppresses medulloblastoma development | Q36509989 | ||
HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling | Q36511804 | ||
Functional evaluation of therapeutic response for a mouse model of medulloblastoma | Q36630089 | ||
Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy | Q36736714 | ||
Nuclear factor-kappaB in development, prevention, and therapy of cancer | Q36743433 | ||
Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells | Q36826672 | ||
NFKBIA deletion in glioblastomas | Q36839660 | ||
The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia. | Q36842360 | ||
Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier | Q36893244 | ||
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma | Q36929844 | ||
Bortezomib for the treatment of mantle cell lymphoma | Q36944390 | ||
Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma | Q37002410 | ||
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials | Q37017342 | ||
Homeostatic functions of the p53 tumor suppressor: regulation of energy metabolism and antioxidant defense | Q37107268 | ||
Medulloblastoma stem cells | Q37186416 | ||
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors | Q37187543 | ||
The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein | Q37187752 | ||
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature | Q37198339 | ||
Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge | Q37729676 | ||
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues | Q37798898 | ||
Deubiquitinases in the regulation of NF-κB signaling | Q37814068 | ||
Novel functions for the anaphase-promoting complex in neurobiology. | Q37857958 | ||
Treatment of high-grade glioma in children and adolescents | Q37904503 | ||
Hedgehog/Gli control by ubiquitination/acetylation interplay. | Q37990685 | ||
Mdm2 and MdmX partner to regulate p53. | Q38016717 | ||
The ubiquitin-proteasome system in glioma cell cycle control | Q38028002 | ||
The complexity of NF-κB signaling in inflammation and cancer | Q38126565 | ||
Oncoprotein stabilization in brain tumors. | Q38156100 | ||
Proteasome Activation by Small Molecules. | Q38702001 | ||
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma | Q28833173 | ||
Mechanisms of Wnt signaling in development | Q29547537 | ||
Role of platelet-derived growth factors in physiology and medicine | Q29615222 | ||
PI3K pathway alterations in cancer: variations on a theme | Q29615530 | ||
Modes of p53 regulation | Q29615657 | ||
Structure and function of the blood-brain barrier | Q29615699 | ||
Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27 | Q29617346 | ||
Convergence of Wnt, beta-catenin, and cadherin pathways | Q29619504 | ||
Building ubiquitin chains: E2 enzymes at work | Q29619578 | ||
Inflammation meets cancer, with NF-κB as the matchmaker | Q29620242 | ||
Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium | Q30481789 | ||
Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products | Q30685494 | ||
Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. | Q30764187 | ||
The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study | Q30779094 | ||
Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy | Q33357936 | ||
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma | Q33363081 | ||
Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). | Q33363903 | ||
United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy | Q33371230 | ||
Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma | Q33388541 | ||
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors. | Q33396761 | ||
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study | Q33398291 | ||
Selective small molecule compounds increase BMP-2 responsiveness by inhibiting Smurf1-mediated Smad1/5 degradation | Q33614939 | ||
Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells. | Q33655371 | ||
Bortezomib reverses a post-translational mechanism of tumorigenesis for patched1 haploinsufficiency in medulloblastoma. | Q33772264 | ||
Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage | Q33798624 | ||
Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo | Q33872837 | ||
Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease | Q33990951 | ||
Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding | Q33994984 | ||
Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects | Q34045104 | ||
Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells. | Q34088521 | ||
Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex | Q34092896 | ||
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas | Q34167499 | ||
Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas | Q34191508 | ||
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations | Q34248736 | ||
Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance | Q34255631 | ||
ATP-dependent incorporation of 20S protease into the 26S complex that degrades proteins conjugated to ubiquitin | Q34310551 | ||
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies | Q39009613 | ||
Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. | Q39173934 | ||
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination | Q39443721 | ||
FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression | Q39904718 | ||
Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome | Q40115986 | ||
Degradation of Id2 by the anaphase-promoting complex couples cell cycle exit and axonal growth. | Q40261081 | ||
Phosphatidylinositol 3'-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. | Q40278543 | ||
Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells | Q40333252 | ||
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib | Q40431708 | ||
Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). | Q40494554 | ||
Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy | Q40498974 | ||
Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model | Q40550633 | ||
Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway | Q41249327 | ||
Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers | Q41264935 | ||
The interferon-gamma-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro | Q41283840 | ||
A mouse model of the most aggressive subgroup of human medulloblastoma | Q41484437 | ||
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses | Q41779891 | ||
Quantification and pharmacokinetics of blood-brain barrier disruption in humans | Q42552409 | ||
Hedgehog signaling promotes the degradation of tumor suppressor Sufu through the ubiquitin-proteasome pathway | Q42806637 | ||
Ubiquitylation of the amino terminus of Myc by SCF(β-TrCP) antagonizes SCF(Fbw7)-mediated turnover | Q42820389 | ||
Inverse relationship between p27/Kip.1 and the F-box protein Skp2 in human astrocytic gliomas by immunohistochemistry and Western blot | Q44074040 | ||
A human brain tumor-derived PDGFR-alpha deletion mutant is transforming | Q44303994 | ||
Endocytosis of Receptor Tyrosine Kinases Is Driven by Monoubiquitylation, Not Polyubiquitylation | Q44420471 | ||
The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription | Q44455864 | ||
PDGF stimulates the massive expansion of glial progenitors in the neonatal forebrain | Q44704841 | ||
Suppressor of fused controls mid-hindbrain patterning and cerebellar morphogenesis via GLI3 repressor. | Q44818348 | ||
Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas | Q44927492 | ||
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. | Q45969598 | ||
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides | Q46380819 | ||
Tyrosine kinase expression in pediatric high grade astrocytoma | Q46809466 | ||
Bone morphogenetic protein 2 opposes Shh-mediated proliferation in cerebellar granule cells through a TIEG-1-based regulation of Nmyc. | Q46939297 | ||
Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas | Q48327574 | ||
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma | Q48329991 | ||
Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma | Q48473042 | ||
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial | Q48599660 | ||
Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma. | Q53243559 | ||
Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. | Q53320286 | ||
Beta-catenin nuclear activation: common pathway between Wnt and growth factor signaling in vascular smooth muscle cell proliferation? | Q53583848 | ||
Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. | Q55462417 | ||
Proteasome inhibitors: from research tools to drug candidates | Q34341985 | ||
New cytotoxic salinosporamides from the marine Actinomycete Salinispora tropica | Q34437864 | ||
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib | Q34467271 | ||
Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities | Q34488856 | ||
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome | Q34501396 | ||
FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation | Q34577722 | ||
APC/CCdc20targets E2F1 for degradation in prometaphase | Q34619596 | ||
Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies | Q34788181 | ||
Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL. | Q34802998 | ||
Roles of F-box proteins in cancer | Q35012352 | ||
PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo | Q35080265 | ||
Molecular subgroups of medulloblastoma | Q35101347 | ||
NF-kappaB and cancer: how intimate is this relationship | Q35143597 | ||
Proteomic screen reveals Fbw7 as a modulator of the NF-κB pathway. | Q35160414 | ||
Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases | Q35169572 | ||
Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts | Q35175677 | ||
Shh signaling protects Atoh1 from degradation mediated by the E3 ubiquitin ligase Huwe1 in neural precursors. | Q35194132 | ||
Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs | Q35269634 | ||
Activation of the heat-stable polypeptide of the ATP-dependent proteolytic system | Q35414574 | ||
Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases | Q35691555 | ||
APC mutations in sporadic medulloblastomas | Q35745470 | ||
Genetic pathways to primary and secondary glioblastoma | Q35757144 | ||
The development of proteasome inhibitors as anticancer drugs | Q35773857 | ||
An animal model of MYC-driven medulloblastoma | Q35774418 | ||
Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma | Q35919057 | ||
Myc proteins in brain tumor development and maintenance | Q35920494 | ||
Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor | Q35925413 | ||
Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct | Q35960250 | ||
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis | Q35997166 | ||
Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors | Q36010873 | ||
The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis | Q36029051 | ||
SCF(Fbw7) modulates the NFkB signaling pathway by targeting NFkB2 for ubiquitination and destruction. | Q36033829 | ||
P433 | issue | 4 | |
P921 | main subject | brain tumor | Q233309 |
P304 | page(s) | 617-633 | |
P577 | publication date | 2017-10-25 | |
P1433 | published in | Cancer and Metastasis Reviews | Q2647982 |
P1476 | title | The ubiquitin-proteasome pathway in adult and pediatric brain tumors: biological insights and therapeutic opportunities | |
P478 | volume | 36 |